Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma
Authors
Keywords
-
Journal
Hepatobiliary & Pancreatic Diseases International
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-08-09
DOI
10.1016/j.hbpd.2022.08.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
- (2022) Ruyin Chen et al. Cancer Cell International
- PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma
- (2022) Li-Gong Lu et al. GUT
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Harnessing cytokines and chemokines for cancer therapy
- (2022) David J. Propper et al. Nature Reviews Clinical Oncology
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- (2022) Vicky Makker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
- (2022) Roger Esteban-Fabró et al. CLINICAL CANCER RESEARCH
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
- (2021) Josep M. Llovet et al. Nature Reviews Gastroenterology & Hepatology
- CAR-T cells and BiTEs in solid tumors: challenges and perspectives
- (2021) Julien Edeline et al. Journal of Hematology & Oncology
- Advances in immunotherapy for hepatocellular carcinoma
- (2021) Bruno Sangro et al. Nature Reviews Gastroenterology & Hepatology
- P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
- (2021) B. Sangro et al. ANNALS OF ONCOLOGY
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC
- (2021) Chenhe Yi et al. HEPATOLOGY
- Immunomodulatory effects of lenvatinib plus anti‐PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma
- (2021) Laura Torrens et al. HEPATOLOGY
- Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
- (2021) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma
- (2021) Haijing Deng et al. Journal for ImmunoTherapy of Cancer
- VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
- (2021) R.K. Kelley et al. ANNALS OF ONCOLOGY
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
- (2021) Thomas Yau et al. LANCET ONCOLOGY
- Cytokines as potential combination agents with PD‐1/PD‐L1 blockade for cancer treatment
- (2020) Ghasem Rahimi Kalateh Shah Mohammad et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased neutrophil extracellular traps promote metastasis potential of hepatocellular carcinoma via provoking tumorous inflammatory response
- (2020) Lu-Yu Yang et al. Journal of Hematology & Oncology
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Haijing Deng et al. Liver Cancer
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
- (2020) Naoshi Nishida et al. Cancers
- Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design
- (2020) Robin Kate Kelley et al. Future Oncology
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial
- (2020) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy
- (2020) Enric Vercher et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Matthias Pinter et al. JAMA Oncology
- Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
- (2020) Yunfan Sun et al. CELL
- The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors
- (2020) Matthew H Taylor et al. Future Oncology
- WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
- (2019) Jason J. Luke et al. CLINICAL CANCER RESEARCH
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Translation control of the immune checkpoint in cancer and its therapeutic targeting
- (2019) Yichen Xu et al. NATURE MEDICINE
- Interferons α and β in cancer: therapeutic opportunities from new insights
- (2019) Ernest C. Borden NATURE REVIEWS DRUG DISCOVERY
- Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
- (2019) Parisa Malekzadeh et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
- (2019) Ying Zhu et al. GUT
- RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
- (2019) Shukui Qin et al. Future Oncology
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
- (2019) Fangjun Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical development of targeted and immune based anti-cancer therapies
- (2019) N. A. Seebacher et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Immune cell therapy for hepatocellular carcinoma
- (2019) Eishiro Mizukoshi et al. Journal of Hematology & Oncology
- Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
- (2019) Xiuqi Wu et al. MOLECULAR THERAPY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
- (2019) Marina Ruiz de Galarreta et al. Cancer Discovery
- Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
- (2019) M. Moehler et al. OncoImmunology
- The Immunobiology of Hepatocellular Carcinoma in Humans and Mice: Basic Concepts and Therapeutic Implications
- (2019) Jiajie Hou et al. JOURNAL OF HEPATOLOGY
- Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
- (2019) Qiming Zhang et al. CELL
- Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches
- (2019) Maria Tagliamonte et al. CANCER LETTERS
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
- (2018) Tong Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis
- (2018) Dirk J. van der Windt et al. HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- The immunology of hepatocellular carcinoma
- (2018) Marc Ringelhan et al. NATURE IMMUNOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potentiating cancer vaccine efficacy in liver cancer
- (2018) Maria Tagliamonte et al. OncoImmunology
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
- (2018) Diwakar Davar et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma
- (2018) Su Jong Yu et al. JOURNAL OF HEPATOLOGY
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
- (2018) Yong Liang et al. Nature Communications
- Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
- (2017) Guoying Zhou et al. GASTROENTEROLOGY
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy
- (2017) Jingying Zhou et al. GUT
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
- (2017) Nicole Glodde et al. IMMUNITY
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
- (2017) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
- (2017) David Kung-Chun Chiu et al. Nature Communications
- The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion
- (2017) Runqiu Jiang et al. Nature Communications
- Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
- (2017) Zhiwu Jiang et al. Frontiers in Immunology
- Abstract 2226: Anti-human PD-1 antibody BGB-A317 exhibits potent immune cell activation
- (2016) Tong Zhang et al. CANCER RESEARCH
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26
- (2016) David Kung-Chun Chiu et al. HEPATOLOGY
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
- (2016) X. Xiao et al. Cancer Discovery
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- (2015) Rony Dahan et al. CANCER CELL
- Developments in cancer vaccines for hepatocellular carcinoma
- (2015) Luigi Buonaguro et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High Serum Transforming Growth Factor- 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib
- (2015) T.-H. Lin et al. CLINICAL CANCER RESEARCH
- Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma
- (2015) Joon Hyeok Lee et al. GASTROENTEROLOGY
- Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
- (2015) Xiaoguang Li et al. GUT
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
- (2015) Tim F Greten et al. GUT
- Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
- (2015) Marta Garnelo et al. GUT
- Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma
- (2015) Juling Ji et al. HEPATOLOGY
- Liver inflammation abrogates immunological tolerance induced by Kupffer cells
- (2015) Felix Heymann et al. HEPATOLOGY
- Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion
- (2015) Martin Franz Sprinzl et al. JOURNAL OF HEPATOLOGY
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
- (2014) M. F. Sanmamed et al. CLINICAL CANCER RESEARCH
- Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
- (2014) H. Gao et al. CLINICAL CANCER RESEARCH
- Addition of Local Hepatic Therapy to Sorafenib in Patients with Advanced Hepatocellular Carcinoma (Stage BCLC C)
- (2014) Laura Schmidt et al. DIGESTION
- Enhanced suppressor function of TIM-3+FoxP3+regulatory T cells
- (2014) Anne-Sophie Gautron et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma
- (2013) Jin Hou et al. CANCER CELL
- Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
- (2013) C. J. Breitbach et al. CANCER RESEARCH
- Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality
- (2013) S. Kalathil et al. CANCER RESEARCH
- HLA ligandome tumor antigen discovery for personalized vaccine approach
- (2013) Hans-Georg Rammensee et al. Expert Review of Vaccines
- Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma
- (2013) Yanmei Han et al. HEPATOLOGY
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma
- (2013) Tobias Flecken et al. HEPATOLOGY
- Deciphering and Reversing Tumor Immune Suppression
- (2013) Greg T. Motz et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis
- (2013) Jonathan Cools-Lartigue et al. JOURNAL OF CLINICAL INVESTIGATION
- Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
- (2013) Rakesh K. Jain JOURNAL OF CLINICAL ONCOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Improved affinity AFP-specific T cell receptor for hepatocellular carcinoma
- (2013) Andrew B Gerry et al. Journal for ImmunoTherapy of Cancer
- A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
- (2012) Tim F Greten et al. BMC CANCER
- TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma
- (2012) Pengyuan Yang et al. CANCER CELL
- Tumor-associated neutrophils: friend or foe?
- (2012) Z. G. Fridlender et al. CARCINOGENESIS
- Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
- (2012) Y. Sawada et al. CLINICAL CANCER RESEARCH
- Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma
- (2012) Shao-Lai Zhou et al. HEPATOLOGY
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
- (2012) Ching-Lung Lai et al. HEPATOLOGY
- Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC
- (2012) Mervat El Ansary et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses
- (2012) F. Zhao et al. JOURNAL OF IMMUNOLOGY
- Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma: A Systemic Review
- (2012) Feng Xie et al. PLoS One
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
- (2011) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
- (2011) Kelley A Parato et al. MOLECULAR THERAPY
- Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis
- (2011) Kang-Jie Chen et al. PLoS One
- Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
- (2010) W. Zhang et al. CLINICAL CANCER RESEARCH
- Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection
- (2010) Haijun Zhou et al. GUT
- The inflammatory microenvironment of HCC – The plot becomes complex
- (2010) Jörg Schrader et al. JOURNAL OF HEPATOLOGY
- Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
- (2009) K. Wu et al. CANCER RESEARCH
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
- (2009) Y. Hoshida et al. CANCER RESEARCH
- Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
- (2009) Bastian Hoechst et al. HEPATOLOGY
- MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer
- (2009) Junfang Ji et al. NEW ENGLAND JOURNAL OF MEDICINE
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
- (2008) D. Y. Chiang et al. CANCER RESEARCH
- Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma
- (2008) Darren R. Feldman et al. Clinical Genitourinary Cancer
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
- (2008) Yujin Hoshida et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now